In the US, Nivolumab (nivolumab systemic) is a member of the drug class Anti-PD-1 monoclonal antibodies and is used to treat Colorectal Cancer, Head and Neck Cancer, Hodgkin's Lymphoma, Melanoma, Melanoma - Metastatic, Non-Small Cell Lung Cancer, Renal Cell Carcinoma and Urothelial Carcinoma.
CAS registry number (Chemical Abstracts Service)
Antineoplastic agent: Inhibitor of PD-1 proteins
A genetically engineered, fully human immunoglobulin G4 (IgG4) mA anti programmed death-1/PD-1 antibody.
Immunoglobulin G4-kappa, anti-[Homo sapiensPDCD1 (programmed cell death 1, PD-1, PD1, CD279)], Homo sapiensmonoclonal antibody; gamma4 haevy chain (1-440) [Homo sapiensVH (IGHV3-33*01 (91.80%) -(IGHD)-IGHJ4*01) [8.8.6] (1-113) -IGHG4*01 hinge S10>P (221) (WHO)
- Nivolumabum (Latin)
- Nivolumab (German)
- Nivolumab (French)
- Nivolumab (Spanish)
- Nivolumab (OS: USAN, JAN)
- BMS-936558 (IS)
- MDX-1106 (IS)
- UNII-31YO63LBSN (IS)
- Nivolumab BMS
Bristol-Myers Squibb, Switzerland; Bristol-Myers Squibb, Germany; Bristol-Myers Squibb Pharmaceutical, United Kingdom
Bristol-Myers Squibb, Switzerland; Bristol-Myers Squibb, Germany; Bristol-Myers Squibb, France; Bristol-Myers Squibb, United States; Bristol-Myers Squibb Pharmaceutical, United Kingdom
|JAN||Japanese Accepted Name|
|Rec.INN||Recommended International Nonproprietary Name (World Health Organization)|
|USAN||United States Adopted Name|
|WHO||World Health Organization|
Click for further information on drug naming conventions and International Nonproprietary Names.
Important Notice: The Drugs.com international database is in BETA release. This means it is still under development and may contain inaccuracies. It is not intended as a substitute for the expertise and judgement of your physician, pharmacist or other healthcare professional. It should not be construed to indicate that the use of any medication in any country is safe, appropriate or effective for you. Consult with your healthcare professional before taking any medication.